secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kinnate Biopharma Inc. (—)
CIK:        0001797768
Form:       8-K
Filed at:   2024-03-01T23:59:59+00:00
Accession:  0001140361-24-010648
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 2.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kinnate sells pan-RAF inhibitor exarafenib to Pierre Fabre for up to $31M
-------------------------------------------------------------------------

- Sold global rights to exarafenib and pan-RAF assets to Pierre Fabre for up to $31M ($500K at closing, $30.5M contingent).
- Pierre Fabre assumes up to $5M in trade payables and 100% of ongoing program costs.
- Transaction closed upon signing on Feb 27, 2024; no closing conditions.
- Stockholders to receive net proceeds from $30.5M contingent payment if XOMA deal closes and proceeds received within 5 years.
- $500K closing payment covers transaction expenses; no net proceeds to stockholders from that.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1797768/000114036124010648/0001140361-24-010648-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1797768/000114036124010648/ny20021737x4_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-010648

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer